DULOXETINE AND QUINOLONES
Potent inhibitors of CYP1A2 are expected to increase duloxetine levels. This has been
seen with fluvoxamine (see below) and is predicted to occur with quinolones (e.g.
ciprofloxacin and enoxacin).
The manufacturer advises that concurrent use should be avoided. Note that the
quinolones may interact to varying extents, see quinolones.
seen with fluvoxamine (see below) and is predicted to occur with quinolones (e.g.
ciprofloxacin and enoxacin).
The manufacturer advises that concurrent use should be avoided. Note that the
quinolones may interact to varying extents, see quinolones.